Denali Therapeutics Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Denali Therapeutics Inc. (DNLI) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$188.52 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2022-05-05
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$188.52M.
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$71.82M, a 156.07% decline year-over-year.
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $128.09M.
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$37.46M.
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$213.67M, a 149.96% decline from fiscal 2020.
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $427.69M, a 18287.58% increase from fiscal 2019.
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $2.33M.
- Denali Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was -$140.29M, a 178.58% decline from fiscal 2017.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$188.52M 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | -$213.67M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | -$112.59M 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | -$21.46M 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | -$71.82M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $427.69M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $271.60M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $57.73M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $128.09M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $2.33M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $5.55M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$14.19M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | -$37.46M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$140.29M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | -$173.76M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | -$184.32M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$174.46M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $178.52M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | -$3.58M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $1.45M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$3.10M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $9.56M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |